A recent study using SEER data found that lung cancer patients without insurance or on Medicaid had significantly higher CVD mortality than those with non-Medicaid insurance.38 Lower PD-L1 testing rate and among NSCLC patients on Medicaid compared to those with commercial insurance may further contribute to these disparities.51 Our findings confirm persistent insurance-related survival disparities in NSCLC patients, particularly in CVD mortality, highlighting the need for integrated cancer and CVD management in this vulnerable population. This evidence concerns the gene CD274 and non-small cell lung carcinoma.